LOCALLY ADVANCED RECTAL CANCER (LARC)
Clinical trials for LOCALLY ADVANCED RECTAL CANCER (LARC) explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL CANCER (LARC) trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL CANCER (LARC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink tumors, spare patients from surgery
Disease control Not yet recruitingThis study is testing whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy (XELOX) after chemoradiation works better than chemotherapy alone for patients with a specific type of locally advanced rectal cancer. The goal is to better control the cancer and se…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo attack on tough GI cancers
Disease control Not yet recruitingThis study is testing whether adding two new drugs (zanidatamab and tislelizumab) to standard chemotherapy or radiation works better for people with HER2-positive stomach or colorectal cancers. It will involve about 70 adults with specific types of advanced or spreading cancer. T…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to shrink tough rectal tumors, spare patients surgery
Disease control Not yet recruitingThis study is testing a new treatment approach for people with a specific type of locally advanced rectal cancer that doesn't typically respond well to immunotherapy alone. About 66 participants will receive a short course of radiation, followed by a combination of a new immunoth…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Could a popular weight loss drug help beat rectal cancer?
Disease control Not yet recruitingThis study is testing if adding a weight loss medication (a GLP-1 receptor agonist like semaglutide) to standard pre-surgery cancer treatment improves results for overweight patients with locally advanced rectal cancer. Researchers will compare two groups: one gets the standard t…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: St. James's Hospital, Ireland • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC